<SEC-DOCUMENT>0001615774-19-003462.txt : 20190301
<SEC-HEADER>0001615774-19-003462.hdr.sgml : 20190301
<ACCEPTANCE-DATETIME>20190301164517
ACCESSION NUMBER:		0001615774-19-003462
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190301
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190301
DATE AS OF CHANGE:		20190301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		19650144

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s116482_8k.htm
<DESCRIPTION>FORM 8K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C.&nbsp;20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Pursuant
to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report&nbsp;(Date of earliest event reported): March 1, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><B>NEKTAR
THERAPEUTICS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
Name of Registrant as Specified in Charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-24006</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3134940</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                    or Other Jurisdiction</B></FONT></P>

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        Incorporation)</B></FONT></P>
</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission</B></FONT></P>

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
        Number)</B></FONT></P>
</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
                                    Employer</B></FONT></P>

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P>
</TD></TR>

</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>455
Mission Bay Boulevard South</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>San
Francisco, California 94158</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Offices and Zip Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: (415) 482-5300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;8.01
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
    Events</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 1, 2019, Nektar Therapeutics, a Delaware corporation (&ldquo;Nektar&rdquo;), issued a press release announcing early results
from the ongoing dose-escalation stage of the REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262,
a novel toll-like receptor (TLR) 7/8 against, in combination with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential
IL-2 pathway agonist. A copy of the press release announcing these preliminary data is attached as Exhibit 99.1 to this Current
Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2019, Nektar announced that it would host a webcast conference call with Dr. Adi Diab, Assistant Professor of Melanoma
Medical Oncology at The University of Texas MD Anderson Cancer Center, and company management for analysts and investors during
the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The conference call will be held on Friday, March 1, 2019, at 3:00 p.m.
Pacific Time and is expected to include a presentation and discussion of safety and clinical data from the ongoing dose-escalation
stage of the REVEAL Phase 1/2 clinical study evaluating NKTR-262 in combination with bempegaldesleukin, as well as initial pharmacokinetic
and biomarker data from the study. A recording of this analyst and investor conference call will be available for replay through
April 1, 2019, on Nektar&rsquo;s website, <U>https://ir.nektar.com/events-and-presentations/events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the analyst and investor conference call, Nektar expects to make certain forward-looking statements regarding the potential therapeutic
benefit of NKTR-262 in combination with bempegaldesleukin, future clinical development plans, the timing for the conclusion of
the dose-escalation stage of the REVEAL Phase 1/2 clinical study, the timing for the availability of clinical and other data from
clinical studies, and certain other statements regarding the prospects and potential of Nektar&rsquo;s business, technology platform
and drug candidate pipeline. These forward-looking statements involve substantial risks and uncertainties, including but not limited
to: (i) our statements regarding the therapeutic potential of the combination of NKTR-262 in combination with bempegaldesleukin
are based on findings and observations from ongoing clinical studies and these findings and observations will evolve over time
as more data emerges from the studies (which data may include negative safety and efficacy results); (ii) both NKTR-262 and bempegaldesleukin
are in the early stages of clinical development and the risk of failure for each drug candidate remains high and failure can unexpectedly
occur at any time due to efficacy, safety or other unpredictable factors; (iii) preliminary clinical results from clinical studies,
including results reported in case studies, remain subject to change as a result of final data audit confirmation procedures to
be conducted following completion of the studies and interim data are also subject to the risk that one or more of the clinical
outcomes may materially change as patient enrollment continues and more patient data become available; (iv) the timing of the
commencement and end of clinical studies and the availability of clinical data may be delayed due to regulatory delays, slower
than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical
trial design, or clinical outcomes; (v) scientific discovery of new medical breakthroughs is an inherently uncertain process and
the future success of applying our technology platform to potential new drug candidates (such as NKTR-262 and bempegaldesleukin)
is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (vi) patents may
not issue from our patent applications for our drug candidates (including NKTR-262 and bempegaldesleukin), patents that have issued
may not be held enforceable by a court of law, or additional intellectual property licenses from third parties may be required;
and (vii) certain other important risks and uncertainties set forth in Nektar&rsquo;s Annual Report on Form 10-K for the year
ended December 31, 2018 filed with the Securities and Exchange Commission on March 1, 2019. Any forward-looking statement made
by Nektar at the investor and analyst event will be based only on information currently available to Nektar and speaks only as
of the date on which it is made. Actual results could differ materially from the forward-looking statements made at the investor
and analyst event. Nektar undertakes no obligation to update forward-looking statements whether as a result of new information,
future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><B>Item 9.01</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial
                                         Statements and Exhibits</B></TD></TR></TABLE>


<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>No.</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s116482_ex99-1.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s116482_ex99-1.htm">Press release titled &ldquo;Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting&rdquo; issued by Nektar Therapeutics on March 1, 2019.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark A. Wilson</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    A. Wilson</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
    Counsel and Secretary</I></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    1, 2019</FONT></TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s116482_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0pt 0"><IMG SRC="img001_v1.jpg" ALT="(NEKTAR LOGO"></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nektar
Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage
of the REVEAL Study at 2019 ASCO-SITC Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SAN
FRANCISCO, March 1, 2019 /PRNewswire/ &ndash;</B> Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the
ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of
NKTR-262, a novel toll-like receptor (TLR) 7/8 agonist, in combination with bempegaldesleukin* (NKTR-214 or bempeg), a
CD122-preferential IL-2 pathway agonist. The results were presented today in an oral session at the 2019 ASCO-SITC Clinical
Immuno-Oncology Symposium by Dr. Adi Diab, Assistant Professor of Melanoma Medical Oncology at The University of Texas MD
Anderson Cancer Center (Oral Abstract Session B, Abstract #28, 1:00 p.m. &ndash; 2:15 p.m. PT).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NKTR-262
is designed to induce the body's innate immune response to prime antigen-specific cytotoxic T cells to fight cancer. Bempegaldesleukin
is designed to activate the adaptive immune system to expand and proliferate these specific cancer-fighting T cells in the tumor
microenvironment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We&rsquo;re
excited by the preliminary data from the REVEAL study which demonstrate desirable changes in the tumor micro-environment consistent
with the activation of both the innate and adaptive immune responses induced by NKTR-262 and bempeg,&rdquo; said Dr. Jonathan
Zalevsky, Chief Scientific Officer at Nektar. &ldquo;The early data from REVEAL demonstrate that a comprehensive approach to activating
the body&rsquo;s immune system can drive abscopal anti-tumor responses even in the absence of a checkpoint inhibitor. We are looking forward to the ongoing dose-escalation and planned expansion of the study.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dose-escalation phase of REVEAL is ongoing. As of January 23, 2019, 13 patients were enrolled that were refractory to
all prior therapies known to confer clinical benefit. Key highlights of the data presentation are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
                                         tolerated dose has not been reached and the dose escalation stage of the study is continuing.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
                                         dose cohorts of NKTR-262 intra-tumoral injection combined with fixed dose of bempeg IV
                                         Q3W were well tolerated. Treatment-related adverse events were transient, characterized
                                         by Grade 1-2 flu-like symptoms (69.2%), rash (46.2%), fatigue (46.2%), pruritus (46.2%)
                                         and nausea (30.8%). There were no immune-mediated adverse events or study discontinuations
                                         due to TRAEs.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local
                                         gene expression analysis of the injected tumor along with analysis of blood cells in
                                         system circulation demonstrated comprehensive activation of the immune system, including
                                         increases in the Type I interferon pathway and induction of CD4+, CD8+ and NK cell proliferation.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
                                         evidence of clinical&nbsp;benefit including abscopal responses in non-injected lesions
                                         was observed in the dose-escalation cohort. 11 of 13 patients in dose-escalation were
                                         evaluable for efficacy with at least one on treatment scan. 2 out of 5 evaluable patients
                                         with relapsed/refractory (R/R) melanoma who progressed on more than one prior checkpoint
                                         or I-O therapy experienced confirmed partial responses with 100% and 50% reductions in
                                         target lesions per RECIST 1.1, respectively. 2 out of 2 heavily pre-treated Stage IV
                                         leiomyosarcoma patients and 1 heavily pre-treated triple negative breast cancer patient
                                         experienced stable disease as best response.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the full data presentation made by Dr. Diab is available on Nektar's corporate website at <U>https://www.nektar.com/download_file/663/0</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Analyst
Call </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nektar
will host an analyst conference call featuring Dr. Adi Diab and company management on Friday, March 1, 2019 at 3:00 p.m. PT during
the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The conference call may be accessed by dialing 877-881-2183 (toll-free)
or 970-315-0453 (international) with the conference call passcode 6970019. The webcast and slides for the conference call can
be accessed through a link posted on the Investors section of the Nektar website at <U>https://ir.nektar.com/events-and-presentations/events</U>.
The webcast of the conference call will be available for replay through April 1, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nektar Phase 1/2 REVEAL Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVEAL
is a Nektar-sponsored, open-label, multicenter, dose escalation and dose expansion study evaluating the combination of NKTR-262
administered as an initial intratumoral injection followed by bempeg administered as an IV infusion systemically (doublet).
In the Phase 2 expansion, the study also may evaluate the doublet combination with nivolumab (triplet). During the dose escalation
phases, recommended Phase 2 dose (RP2D) regimens of the doublet and/or triplet combinations will be established. Following dose
escalation, the dose expansion phase will evaluate the doublet and/or triplet combinations in up to 350 patients who have been
diagnosed with a range of locally advanced or metastatic cancers including: melanoma, Merkel cell carcinoma, triple-negative breast
cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, urothelial carcinoma, or sarcoma. For more information, please
visit https://clinicaltrials.gov/ and search NCT03435640.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Bempegaldesleukin (NKTR-214)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bempegaldesleukin
is an investigational, first-in-class, CD122-preferential IL-2 pathway agonist designed to provide rapid activation and proliferation
of cancer-killing immune cells, known as CD8+ effector T cells and natural killer (NK) cells, without over activating the immune
system. Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found
on the surface of these immune cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling
receptor that is known to increase proliferation of these effector T cells.<SUP>1</SUP> In clinical and preclinical studies,
treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment.<SUP>2,3 </SUP>Bempegaldesleukin has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NKTR-262</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer
treatments that couple pharmacological activation of tumor antigen presentation with activation and expansion of CD8+ T and natural
killer (NK) cells in the tumor environment have the potential to induce an effective anti-tumor immune response in patients. NKTR-262
is a novel small molecule agonist designed to activate toll-like receptors (TLRs). Intratumoral delivery of NKTR-262 promotes
TLR activation to induce the development of antigen-specific immunity by initiating the process by which the immune system generates
antigen-specific cytotoxic T cells to the patient's specific tumor.<SUP>4</SUP> Bempeg targets CD122 specific receptors found
on the surface of these cancer-killing immune cells, known as CD8+ effector T cells. By first generating antigen-specific cytotoxic
T cells with NKTR-262 and then growing these CD8+ effector T cells with bempeg, the patient's entire immunity cycle can potentially
be engaged to fight cancer. In preclinical studies, a single intratumoral dose of NKTR-262, administered in combination with bempeg,
resulted in complete abscopal tumor regressions in multiple mouse syngeneic tumor models.<SUP>5</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nektar </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nektar
Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative
medicines to address the unmet medical needs of patients. Our R&amp;D pipeline of new investigational medicines includes treatments
for cancer, auto-immune disease and chronic pain. We leverage our proprietary and proven chemistry platform in the discovery and
design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in
Huntsville, Alabama and Hyderabad, India. Further information about Nektar and its drug development programs and capabilities
may be found online at <U>http://www.nektar.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Forward-Looking
Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements which can be identified by words such as: &quot;will,&quot; &quot;may,&quot;
&quot;can,&quot; &quot;planned,&quot; &quot;designed&quot; and similar references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding the therapeutic potential of NKTR-262 in combination with bempegaldesleukin,
the anticipated initiation and completion of clinical studies, and the timing of the availability of results and outcomes from
our clinical studies. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they
are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,
anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside
of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential
of the combination of NKTR-262 in combination with bempegaldesleukin are based on findings and observations from ongoing clinical
studies and these findings and observations will evolve over time as more data emerges from the studies (which data may include
negative safety and efficacy results); (ii) both NKTR-262 and bempegaldesleukin are in the early stages of clinical development
and the risk of failure for each drug candidate remains high and failure can unexpectedly occur at any time due to efficacy, safety
or other unpredictable factors; (iii) preliminary clinical results from clinical studies, including results reported in case studies,
remain subject to change as a result of final data audit confirmation procedures to be conducted following completion of the studies
and interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment
continues and more patient data become available; (iv) the timing of the commencement and end of clinical studies and the availability
of clinical data may be delayed due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges,
changing standards of care, evolving regulatory requirements, clinical trial design, or clinical outcomes; (v) scientific discovery
of new medical breakthroughs is an inherently uncertain process and the future success of applying our technology platform to
potential new drug candidates (such as NKTR-262 and bempegaldesleukin) is therefore highly uncertain and unpredictable and one
or more research and development programs could fail; (vi) patents may not issue from our patent applications for our drug candidates
(including NKTR-262 and bempegaldesleukin), patents that have issued may not be held enforceable by a court of law, or additional
intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set
forth in Nektar&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange
Commission on March 1, 2019. Any forward-looking statement made by us in this press release is based only on information currently
available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement,
whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Investors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer
Ruddock of Nektar Therapeutics<BR>
415-482-5585</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashleigh
Barreto of Nektar Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">628-895-0694</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Media:<BR>
Jodi Sievers of Nektar Therapeutics<BR>
415-482-5593</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
Budwick of 1AB</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">973-271-6085</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>dan@1abmedia.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Boyman, J., et al., Nature Reviews Immunology, 2012, 12, 180-190.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>Charych, D., et al., Clin Can Res; 22(3) February 1, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP>Diab, A., et al., Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1): P369</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4
</SUP>Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949-964. doi:10.2217/imt.09.70.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5
</SUP>Kivimae, S., et al., Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 2):P275</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
rINN (recommended International Nonproprietary Name)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ (P"L P$1  (1 0,1 ?_$ +$   (# 0$!
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MONC5U*3JY4((^,P-O5XA&5*/F/@/%6[=01^=^H>*#J.S7^M9#])2OOLDD!Q
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=N6[EBZ6S%H[<9Q;^>S'>&";:KE.T%/&--2<O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
